Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus

Clinical Therapeutics

Volumn 35, Issue 10, 2013, Pages 1557-1570

  Puzniak, Laura A ^a   Morrow, Lee E ^b   Huang, David B ^a   Barreto, Jason N ^c  

^a PFIZER INC   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^c Rochester Methodist Hospital   (United States)

Author keywords

CSSSI; Linezolid; MRSA; Nosocomial pneumonia; Vancomycin; Weight

Indexed keywords

LINEZOLID; VANCOMYCIN;

ADULT; ANEMIA; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SKIN INFECTION; SKIN STRUCTURE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

CSSSI; LINEZOLID; MRSA; NOSOCOMIAL PNEUMONIA; VANCOMYCIN; WEIGHT;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; BODY WEIGHT; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84885866108     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.08.001     Document Type: Article

References (51)

1. Flegal K.M., Carroll M.D., Kit B.K., Ogden C.L. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012, 307:491-497.
2. Berghofer A., Pischon T., Reinhold T., et al. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008, 8:200.
3. Kelly T., Yang W., Chen C.S., et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008, 32:1431-1437.
4. Falagas M.E., Karageorgopoulos D.E. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010, 375:248-251.
5. Jain R., Chung S.M., Jain L., et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 2011, 90:77-89.
6. Bearden D.T., Rodvold K.A. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 2000, 38:415-426.
7. Pai M.P., Bearden D.T. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007, 27:1081-1091.
8. Vancomycin hydrochloride; vancomycin hydrochloride injection, solution [package insert]. Deerfield, Ill: Baxter Healthcare Corporation; 2008.
9. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
10. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:e18-e55.
11. Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother 2012, 67:1305-1310.
12. Weigelt J., Itani K., Stevens D., et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005, 49:2260-2266.
13. Wunderink R.G., Niederman M.S., Kollef M.H., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54:621-629.
14. (linezolid) [package insert]. New York, NY: Pfizer Inc; 2006.
15. Stein G.E., Wells E.M. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin 2010, 26:571-588.
16. Gee T., Ellis R., Marshall G., et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001, 45:1843-1846.
17. Meagher A.K., Forrest A., Rayner C.R., et al. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003, 47:548-553.
18. Mersfelder T.L., Smith C.L. Linezolid pharmacokinetics in an obese patient. Am J Health Syst Pharm 2005, 62(464):467.
19. Stein G.E., Schooley S.L., Peloquin C.A., et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005, 39:427-432.
20. Bhalodi A.A., Papasavas P.K., Tishler D.S., et al. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother 2013, 57:1144-1149.
21. Muzevich K.M., Lee K.B. Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature. Ann Pharmacother 2013, 47:e25.
22. Pea F., Viale P., Cojutti P., et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012, 67:2034-2042.
23. Sreeramoju P., Porbandarwalla N.S., Arango J., et al. Recurrent skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus requiring operative debridement. Am J Surg 2011, 201:216-220.
24. Kaye K.S., Marchaim D., Chen T.Y., et al. Predictors of nosocomial bloodstream infections in older adults. J Am Geriatr Soc 2011, 59:622-627.
25. Yosipovitch G., DeVore A., Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol 2007, 56:901-916. (quiz 917-920).
26. Dossett L.A., Dageforde L.A., Swenson B.R., et al. Obesity and site-specific nosocomial infection risk in the intensive care unit. Surg Infect (Larchmt) 2009, 10:137-142.
27. Serrano P.E., Khuder S.A., Fath J.J. Obesity as a risk factor for nosocomial infections in trauma patients. J Am Coll Surg 2010, 211:61-67.
28. Dryden M.S. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2011, 66(Suppl 4). (iv7-iv15).
29. Varon J., Marik P. Management of the obese critically ill patient. Crit Care Clin 2001, 17:187-200.
30. Dossett L.A., Heffernan D., Lightfoot M., et al. Obesity and pulmonary complications in critically injured adults. Chest 2008, 134:974-980.
31. Itani K.M., Dryden M.S., Bhattacharyya H., et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2010, 199:804-816.
32. Hall R.G., Payne K.D., Bain A.M., et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med 2008, 121:515-518.
33. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007, 44:1543-1548.
34. van Hal S.J., Fowler V.G. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?. Clin Infect Dis 2013, 56:1779-1788.
35. Moellering R.C. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003, 138:135-142.
36. Moise-Broder P.A., Forrest A., Birmingham M.C., Schentag J.J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43:925-942.
37. Janson B., Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis 2012, 25:634-649.
38. Kahlon S., Eurich D.T., Padwal R.S., et al. Obesity and outcomes in patients hospitalized with pneumonia. Clin Microbiol Infect 2013, 19:709-716.
39. Falagas M.E., Athanasoulia A.P., Peppas G., Karageorgopoulos D.E. Effect of body mass index on the outcome of infections: a systematic review. Obes Rev 2009, 10:280-289.
40. Hedlund J., Hansson L.O., Ortqvist A. Short- and long-term prognosis for middle-aged and elderly patients hospitalized with community-acquired pneumonia: impact of nutritional and inflammatory factors. Scand J Infect Dis 1995, 27:32-37.
41. Lange P., Vestbo J., Nyboe J. Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. Eur Respir J 1995, 8:1694-1698.
42. Almirall J., Bolibar I., Balanzo X., Gonzalez C.A. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999, 13:349-355.
43. LaCroix A.Z., Lipson S., Miles T.P., White L. Prospective study of pneumonia hospitalizations and mortality of U.S. older people: the role of chronic conditions, health behaviors, and nutritional status. Public Health Rep 1989, 104:350-360.
44. Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation. World Health Organization Technical Report, Series 894 2000, 1-253. World Health Organization., World Health Organization, Geneva, Switzerland.
45. Kalil A.C., Puumala S.E., Stoner J. Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia. Chest 2004, 125:2370-2371.
46. Lahey T. Questionable superiority of linezolid for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: watch where you step. Clin Infect Dis 2012, 55:159-160.
47. Masuta K., Oba Y., Iwata K. Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: controversy continues. Clin Infect Dis 2012, 55:161.
48. Torres A. Antibiotic treatment against methicillin-resistant Staphylococcus aureus hospital- and ventilator-acquired pneumonia: a step forward but the battle continues. Clin Infect Dis 2012, 54:630-632.
49. Bauer T.T. Nosocomial pneumonia: therapy is just not good enough. Chest 2003, 124:1632-1634.
50. Powers J.H., Ross D.B., Lin D., Soreth J. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest 2004, 126:314-315. (author reply 315-316).
51. Wolff M., Mourvillier B. Linezolid for the treatment of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2012, 55:160-161.